<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>三个FDA顾问辞去了机构对阿尔茨海默氏药物的批准 Three FDA Advisers Resign over Agency’s Approval of Alzheimer’s Drug</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">Three FDA Advisers Resign over Agency’s Approval of Alzheimer’s Drug<br/>三个FDA顾问辞去了机构对阿尔茨海默氏药物的批准 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-06-11 11:39:32</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2021/6/4b80cb4559c4aa04d1a28c253abf6060.jpg"><img src="http://img2.diglog.com/img/2021/6/4b80cb4559c4aa04d1a28c253abf6060.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>In a powerful statement of disagreement with the Food and Drug Administration’s approval of Biogen’s controversial Alzheimer’s drug, three scientists have resigned from the independent committee that advised the agency on the treatment.</p><p>在与食品药品监督管理局对生物原生物争夺阿尔茨海默氏药物的批准的强大的分歧陈述中，三家科学家们已经辞去了独立委员会，该委员会向该机构提供了治疗。</p><p> “This might be the worst approval decision that the F.D.A. has made that I can remember,” said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School and Brigham and Women’s Hospital, who submitted his resignation Thursday after six years on the committee.</p><p> “这可能是F.D.A.的最糟糕的决定我可以记住，“哈佛医学院和布里格姆和妇女医院医学教授Aaron Kesselheim博士说，他于周四在委员会六年后提交了辞职。</p><p> He said the agency’s approval of the drug, aducanumab, which is being marketed as Aduhelm, a monthly intravenous infusion that Biogen has priced at $56,000 per year, was wrong “because of so many different factors, starting from the fact that there’s no good evidence that the drug works.”</p><p> 他表示，原子能机构对药物批准的销售作为Aduhelm的销售，每月静脉注射，生物原为每年56,000美元，出错了“因为这么多不同的因素，从事没有良好的证据药物的工作。“</p><p> Two other members of the committee resigned earlier this week, expressing dismay at the approval of the drug despite the committee’s  overwhelming rejection of it after reviewing clinical trial data in November.</p><p> 委员会的另外两名成员本周早些时候辞职，尽管委员会在审查11月审查临床试验数据后，委员会的批准表达了毒品的批准。</p><p> The committee had found that the evidence did not convincingly show that Aduhelm could slow cognitive decline in people in the early stages of the disease — and that the drug could cause potentially serious side effects of brain swelling and brain bleeding. None of the 11 members of the committee considered the drug ready for approval: Ten voted against and one was uncertain.</p><p> 委员会发现，证据表明，疾病早期阶段的人们可能会缓慢认知的人们对脑肿胀和脑出血的潜在严重副作用。委员会的11名成员中没有一部分审议药物准备批准：十项投票反对，一个是不确定的。</p><p> “Approval of a drug that is not effective has serious potential to impair future research into new treatments that may be effective,” said Dr. Joel Perlmutter, a neurologist at Washington University School of Medicine in St. Louis, who was the first to resign from the committee.</p><p> “批准未效益的药物具有严重潜在的潜在可能损害可能是有效的新治疗的研究，”华盛顿大学医学院的神经科医学院乔尔佩尔曼博士说，圣路易斯圣路易斯首先是辞职来自委员会。</p><p> “In addition, the implementation of aducanumab therapy will potentially cost billions of dollars, and these dollars may be better spent in either developing better evidence for aducanumab or other therapeutic interventions,” Dr. Perlmutter added.</p><p> “此外，Aducanumab治疗的实施可能会花费数十亿美元，并且在佩尔莫特博士补充说，这些美元可能更好地花费更好的证据。” </p><p> Shannon P. Hatch, a spokeswoman for the F.D.A., said the agency does not comment on matters related to individual members of advisory committees.</p><p>Shannon P.F.D.A的发言人哈奇表示，该机构不评论与咨询委员会的个人成员有关的事项。</p><p> Biogen plans to begin shipping out the drug in about two weeks. It expects more than 900 sites across the country, typically memory clinics that see patients with dementia, to soon be ready to administer the drug.</p><p> Biogen计划在大约两周内开始发运药物。它预计全国各地的900多个网站，通常会看到患有痴呆症患者的记忆诊所，即很快就可以施用药物。</p><p> The F.D.A.’s  decision to green-light it, announced Monday, marked the first approval of an Alzheimer’s treatment in 18 years. Patient advocacy groups had pushed for approval because there are only five other  medications available for the debilitating condition and they only address dementia symptoms for a matter of months.</p><p> F.D.A.周一宣布的绿灯的决定标志着18年来第一次批准阿尔茨海默治疗。患者倡导团体推动批准，因为只有五种其他药物可用于衰弱的病症，它们只能解决月份的痴呆症状。</p><p> But since at least last fall, several respected experts, including some  Alzheimer’s doctors who worked on the aducanumab clinical trials, have said the available  evidence raised significant doubts about whether the drug is effective. They also said that even if it could slow cognitive decline in some patients, the suggested benefit — a slowing of symptoms for roughly four months over 18 months — might be barely noticeable to patients and would not outweigh the risks of brain side effects.</p><p> 但从最后一次堕落以来，几个受尊重的专家，包括一些在达uCanumab临床试验上工作的阿尔茨海默家族，已表示可用的证据表明药物是否有效地提出了显着的疑虑。他们还表示，即使它可能会缓慢患者的认知下降，建议的好处 - 症状减缓超过4个月超过18个月 - 可能对患者几乎没有突出，并且不会超过脑副作用的风险。</p><p> Beyond the steep price tag of the drug, additional costs to screen patients before treatment and for regular MRIs required to monitor their brains for problems could add tens of thousands of dollars to the tab. Medicare is expected to shoulder much of the bill.</p><p> 除了药物的陡峭价格标签之外，治疗前筛选患者的额外成本和常规的MRIS需要监测他们的大脑的问题，可以增加数万美元到标签。 Medicare预计将承担大部分账单。</p><p> “Giving patients a drug that doesn’t work and of course has important risks that are going to require multiple MRIs at a price of $56,000 a year is putting patients in a really challenging position and putting doctors in a difficult position as well,” Dr. Kesselheim said.</p><p> “给患者给患者一种不起作用的药物，当然有一个重要的风险，将以每年56,000美元的价格要求患者在一个非常具有挑战性的立场，并将医生在困境中置于困境，”博士。Kesselheim说。</p><p> Beyond their conviction that the existing evidence for Aduhelm’s benefit is weak, the advisory committee members who resigned — as well as several prominent Alzheimer’s experts — objected to two major aspects of the F.D.A.’s approval decision.</p><p> 除了定罪之外，即副议员福利的现有证据是薄弱的，咨询委员会成员辞职 - 以及几位着名的阿尔茨海默氏专家 - 反对F.D.A.批准决定的两个主要方面。 </p><p> One issue is that the F.D.A. approved the drug for a much broader group of patients — anyone with Alzheimer’s — than many experts were anticipating. The clinical trials tested the drug only on patients with early-stage Alzheimer’s or mild cognitive impairment from the disease.</p><p>一个问题是f.d.a.为一个更广泛的患者批准了药物 - 任何有阿尔茨海默氏症的人 - 超过了许多专家。临床试验仅对患有早期阿尔茨海默氏症或轻度疾病的患者的药物测试了该药。</p><p> The other issue is that a significant part of the F.D.A.’s rationale for granting approval was its contention that the drug’s ability to attack the amyloid protein in patients’ brains would help slow their cognitive symptoms.</p><p> 另一个问题是，授予批准的一部分是F.D.A.理由的理由是其争夺药物攻击患者大脑中淀粉样蛋白蛋白的能力将有助于缓慢他们的认知症状。</p><p> While amyloid is considered a biomarker of Alzheimer’s disease because its accumulation in the brain is a key facet of the condition, there has been very little scientific evidence that reducing amyloid can actually help patients by easing their memory and thinking problems.</p><p> 虽然淀粉样蛋白被认为是阿尔茨海默病的生物标志物，因为它在大脑中的积累是条件的关键方面，但还有很少的科学证据，即还原淀粉样蛋白实际上可以通过缓解记忆和思维问题来帮助患者。</p><p> Clinical trials of other amyloid-reducing drugs over more than two decades have failed to offer evidence that the medications slowed cognitive decline. Consequently, many experts had said it was especially important to have solid evidence for Aduhelm’s ability to address symptoms.</p><p> 超过二十年的其他淀粉样蛋白还原药的临床试验未能提供有证据表明药物减缓认知下降。因此，许多专家表示，对于具有妥善证据来解决症状的能力尤为重要。</p><p> In November, F.D.A. officials told the advisory committee members that the agency would not be counting the drug’s ability to reduce amyloid as an indication that it might be effective. But in Monday’s decision, the F.D.A. announced that it had done just that.</p><p> 11月，F.D.A.官员告诉咨询委员会成员，该机构不会计算药物减少淀粉样蛋白的能力，以表明它可能是有效的。但在周一的决定，F.D.A.宣布它已经做到了。</p><p> “FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients,” the F.D.A.’s director of the Center for Drug Evaluation and Research, Dr. Patrizia Cavazzoni,  wrote on the agency’s website about the decision to make the drug available under a program called  accelerated approval.</p><p> “FDA已确定存在大量证据表明Aduhelm降低了大脑中的淀粉样蛋白β斑块，并且这些斑块的减少合理可能预测患者的重要益处，”药物评估和研究中心FDA董事“， Patrizia Cavazzoni博士在原子能机构的网站上写了关于使药物在称为加速批准的方案下提供的决定。</p><p> But advisory committee members said the committee was never told that the agency was planning to consider approval based on amyloid reduction and that their opinion was never sought about that significant change. Dr. Perlmutter said the committee was “not made aware of any additional information or statistical analyses that would support” approval.</p><p> 但咨询委员会成员表示，委员会从未被告知该机构计划考虑基于淀粉样式的审批，并且他们的意见从未寻求过大重大变化。 PerlMutter博士表示，委员会“没有意识到将支持”批准的任何其他信息或统计分析。 </p><p> Dr. David Knopman, a clinical neurologist at the Mayo Clinic, wrote in an email to F.D.A. officials informing them of his resignation from the advisory committee on Wednesday: “Biomarker justification for approval in the absence of consistent clinical benefit after 18 months of treatment is indefensible.”</p><p>梅奥诊所的临床神经科医生David Knopman博士在电子邮件中写给F.D.A.官员在周三向咨询委员会通知他们辞职：“在18个月的治疗后，在没有一致的临床益处的情况下，批准的生物标志性理由是无可辩驳的。”</p><p> Dr. Knopman, who had recused himself from the November meeting because he had served as a site principal investigator for one of the aducanumab trials, added that “the whole saga of the approval of aducanumab, culminating on Monday in the accelerated approval, made a mockery” of the advisory committee’s role.</p><p> 诺克曼博士，他从11月的会议上抵抗了自己，因为他曾担任一项现场主要调查人员，这是一项土城武成试验的网站主要调查员，并补充说“奥克兰州批准的整个传奇，周一在加速批准的周一上最终得到了最终嘲弄“咨询委员会的角色。</p><p>  Dr. Peter Stein, who directs the F.D.A. Center for Drug Evaluation and Research’s Office of New Drugs, said in a briefing with reporters after the decision that agency reviewers were persuaded by what he described as a strong relationship between plaque reduction and potential clinical benefit with Aduhelm, which he said had not been seen in previous studies of drugs designed to clear amyloid.</p><p>  Peter Stein博士，指导F.D.A.毒品评估和研究中的新药办事处，在讲述代理审查人员被说服的决定之后向记者介绍了他所说的牌匾减少与Aduhelm潜在临床效益之间的强大关系，他说没有看到在以前的研究中设计用于清除淀粉样蛋白的药物。</p><p> Dr. Stein also defended the agency’s decision to approve the drug for such a broad group of patients, saying it could be relevant beyond the early stages of Alzheimer’s.</p><p> 斯坦德博士还捍卫了原子能机构为这类广泛患者批准药物的决定，称它可能与阿尔茨海默氏症的早期阶段相关。</p><p> “Because amyloid is a hallmark of the disease through its entire course, the expectation is that this drug will provide benefit across that spectrum,” Dr. Stein said.</p><p> “因为淀粉样蛋白是疾病的标志，通过其整个课程，期望是这种药物将在这种频谱中提供益处，”斯坦德博士说。</p><p> As a condition for the approval, the F.D.A. said it would require Biogen to conduct another clinical trial and would allow the company about nine years to complete it. Those terms also concern some experts. They say that during those years the drug will be available without restriction, and if the new trial does not find the drug beneficial, the agency can revoke its approval, but it is not required to and has not always done so with other drugs.</p><p> 作为批准的条件，F.D.A.说它需要生物原性来进行另一次临床试验，并允许该公司完成九年来完成它。这些术语也涉及一些专家。他们说，在那些年份，药物将在没有限制的情况下提供，如果新的审判没有找到毒品有益，则该机构可以撤销其批准，但不需要与其他药物一起做出。</p><p> “The timeline that they provided for the so-called confirmatory trial, nine years, is problematic,” said Dr. Kesselheim, who also directs Harvard Medical School’s program on regulation, therapeutics and law. “There’s going to be a lot of use of the product during that time.”</p><p> “他们为所谓的确认审判提供的时间表，九年是有问题的，”克塞尔海姆博士表示，他还指导哈佛医学院的监管，治疗和法律计划。 “在此期间，产品将会有很多使用。” </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://www.nytimes.com/2021/06/10/health/aduhelm-fda-resign-alzheimers.html">https://www.nytimes.com/2021/06/10/health/aduhelm-fda-resign-alzheimers.html</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/顾问/">#顾问</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/advisers/">#advisers</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/药物/">#药物</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy;2012-2021 diglog.com </div></div></body></html>